Nivolumab Approved for MSI-H, dMMR Metastatic Colorectal Cancer

The FDA has granted accelerated approval to nivolumab for use in adult and adolescent patients with MSI-H or dMMR metastatic colorectal cancer.

Source: CancerNetwork - August 14, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Colorectal Cancer News Pediatric Cancers Source Type: news